Anti-aging graduated from fringe — now comes the hard part

Anti-aging graduated from fringe — now comes the hard part

Silicon Valley billionaires are funding cellular reprogramming and senolytic drug research, biotech billions are flowing into Altos Labs and Calico, and Bryan Johnson remains the poster child for extreme biohacking. The money is real. The ambition is real. But the framing that matters most is still this: lifespan is not healthspan, and extra years spent in decline are not the prize anyone is actually after.

Gobble's Take: Longevity went from lab curiosity to status sport — but healthspan is where the bragging rights get settled. Source: Perplexity Search (community: Reddit/HN)

Two short peptides are making outsized noise in regenerative circles

Epitalon and Pinealon — short synthetic peptides in the bioregulator class — are drawing attention for their possible influence over gene expression, cellular communication, and tissue repair. The catch is straightforward: much remains experimental, and neither peptide has received widespread regulatory approval for anti-aging medicine in many countries.

Gobble's Take: Sounds like tomorrow's medicine. Looks like today's controversy. Both things can be true. Source: Perplexity Search (community news)

In Case You Missed It

Yesterday's top stories:

• The annual physical was built for a different century
• Sleep regularity is the lever most people ignore